Topical Tyrosine vs. Topical 5-Fluorouracil with Fractional Erbium:YAG Laser for focal vitiligo
Official title: Efficacy of Topical Tyrosine Versus Topical 5-Fluorouracil With Fractional Erbium YAG Laser in Focal Vitiligo: A Randomised Clinical Trial
Run by Aswan University · NCT07742982 · Data updated 2026-11-12
This study tests whether applying Tyrosine topically works for focal vitiligo in adults compared with a standard topical treatment when combined with a fractional Erbium:YAG laser.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Aswan University Academic / other |
| Locations | 1 site (Aswān) |
| Status | Recruiting |
| Started | June 1, 2026 |
| Main results expected | June 1, 2027 |
| Study ends | June 10, 2027 |
| Registry record updated | August 11, 2026 |
| Trial ID | NCT07742982 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with focal vitiligo, excluding those with segmental vitiligo, pregnancy or lactation, autoimmune disease, chronic systemic diseases, or active skin infections.
✕Probably not a fit
Patients with segmental vitiligo, those with autoimmune or chronic conditions, or those unable to undergo laser-assisted treatment may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This early-phase trial examines the safety and preliminary effectiveness of topical Tyrosine compared with topical 5-fluorouracil when used alongside fractional Erbium:YAG laser therapy for focal vitiligo. Participants have focal vitiligo and no segmental disease, with exclusions including pregnancy, lactation, autoimmune disease, and active infections. The intervention uses Tyrosine as the active topical agent; the comparator uses 5-fluorouracil, both delivered with laser-assisted treatment. Outcomes focus on repigmentation and tolerability over a defined follow-up period. The trial is conducted at Aswan University Hospital with lead sponsorship by Aswan University.
Why it matters
Potential benefit: If successful, participants may experience improved repigmentation and symptom relief with a tolerable safety profile when using topical Tyrosine in combination with laser therapy.
How similar studies have gone: Previous approaches combining topical agents with laser therapy have shown variable repigmentation; this study explores a novel topical agent in a similar framework.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Patients with focal vitiligo Exclusion Criteria: * Pregnancy. * Lactation. * Patients with segmental vitiligo. * Patients with autoimmune disease including thyroiditis. * Patients with chronic systemic diseases,such as anemia ,diabetes mellitus, immunosuppression, or chronic infections. * Patients with active skin infections.
Where it's running
-
Aswan University Hospital
Aswān, Egypt Recruiting
Study contacts
- Study coordinator: Yasmin Mahdy Mohamed Ahmed, MSC
- Email: yasmin17041133@aswu.edu.eg
- Phone: +201126607448
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.